

External validation of a claims-based model to predict left ventricular ejection fraction class in patients with heart failure

Mufaddal Mahesri;¹ Kristyn Chin;¹ Abheenava Kumar;² Aditya Barve;³ Rachel Studer;⁴ Raquel Lahoz;⁴ Rishi J. Desai;¹

¹ Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital & Harvard Medical School, Boston, MA, USA.

² Novartis Healthcare Pvt. Ltd., Hyderabad, India

³ Novartis Ireland Pvt. Ltd, Dublin, Ireland

⁴ Novartis Pharma AG, Basel, Switzerland

Correspondance :

Rishi J Desai, MS, PhD

Division of Pharmacoepidemiology and Pharmacoeconomics,

Department of Medicine, Brigham and Women's Hospital and Harvard Medical School,

1620 Tremont Street, Suite 3030-R, Boston, MA 02120, USA

Phone: 617-278-0932 | Fax: 617-232-8602 | Email: rdesai@bwh.harvard.edu

Word count: Abstract= 250 words;

Main body of text (excluding abstract, tables/figures, and references) = 1,585 words.

ABSTRACT

BACKGROUND:

Ejection fraction (EF) is an important prognostic factor in heart failure (HF), but administrative claims databases lack information on EF. We previously developed a model to predict EF class from Medicare claims. Here, we evaluated the performance of this model in an external validation sample of commercial insurance enrollees.

METHODS:

Truven MarketScan claims linked to electronic medical records (EMR) data (IBM Explorys) containing EF measurements were used to identify a cohort of US patients with HF between 01-01-2012 and 10-31-2019. By applying the previously developed model, patients were classified into HF with reduced EF (HF_rEF) or preserved EF (HF_pEF). EF values recorded in EMR data were used to define gold-standard HF_pEF (LVEF $\geq 45\%$) and HF_rEF (LVEF $< 45\%$). Model performance was reported in terms of overall accuracy, positive predicted values (PPV), and sensitivity for HF_rEF and HF_pEF.

RESULTS:

A total of 7,001 HF patients with an average age of 71 years were identified, 1,700 (24.3%) of whom had HF_rEF. An overall accuracy of 0.81 (95% CI: 0.80-0.82) was seen in this external validation sample. For HF_pEF, the model had sensitivity of 0.96 (95%CI, 0.95-0.97) and PPV of 0.81 (95% CI, 0.81-0.82); while for HF_rEF, the sensitivity was 0.32 (95%CI, 0.30-0.34) and PPV was 0.73 (95%CI, 0.69-0.76). These results were consistent with what was previously published in US Medicare claims data.

CONCLUSIONS:

The successful validation of the Medicare claims-based model provides evidence that this model may be used to identify patient subgroups with specific EF class in commercial claims databases as well.

INTRODUCTION

Ejection fraction (EF) is an important prognostic factor in heart failure (HF). HF with reduced ejection fraction (HFrEF) is well characterized and there are a number of evidence-based therapies available.¹ In contrast, HF with preserved EF (HFpEF) is more heterogeneous, poorly characterized and there are no approved therapies that improve outcomes.¹

Insurance claims databases allow for longitudinal follow-up at the patient level and are very useful in evaluation of disease epidemiology and treatment outcomes in routine care.² However, a major limitation with claims databases in studying HF is the lack of available results from procedures such as echocardiograms or cardiac catheterization, which are used to measure EF. Consequently, one cannot directly distinguish between HFrEF and HFpEF based on administrative claims. To address this limitation, we previously developed a model to predict EF class using Medicare claims and validated using electronic medical record (EMR) data from two large healthcare provider networks from the Boston metropolitan area.³ The primary objective of the current study was to evaluate the performance of this prediction model in an external validation cohort.

METHODS

Data Source

Claims data derived from the Truven MarketScan database linked to EMRs from the IBM Exploryst database were used. Truven MarketScan covers 235 million lives of US citizens consisting of two core claims databases; 1) MarketScan Commercial Claims and Encounters - which contains healthcare data commercially insured individuals, encompassing employees, their spouses, and their dependents from the United States, 2) Medicare Supplemental and Coordination of Benefits - which contains the healthcare experiences of Medicare-eligible retirees with employer-sponsored Medicare Supplemental plans. Both these data sources contain longitudinally traceable information for their enrollees' medical

diagnoses recorded with International Classification of Disease, 9th and 10th Clinical Modification (ICD-9/ICD-10 CM) codes, medical procedures recorded as Current Procedure Terminology (CPT) or ICD-9 procedure codes, and medication dispensing recorded using National Drug Codes (NDC). The IBM Explorys data platform is a data network that comprises integrated information from 360 hospitals and approximately 31,700 providers, covering approximately 50 million patient lives. The Explorys data has been used for multiple prior observational studies⁴⁻⁷ and contain data derived from ambulatory electronic medical records (EMRs), inpatient EMRs, laboratory, pharmacy, health plans, billing and accounting, data warehouses, patient portals, satisfaction surveys, and care management systems. The MarketScan and Explorys linked population represent approximately 10% of the total MarketScan population.

Study Design

Adult patients were included in the study if they had ≥ 1 diagnosis code for HF (ICD-9 or ICD-10) from the Truven MarketScan claims database after 6 months of continuous enrollment in their health plans and ≥ 1 recorded EF result, within 6 months prior or 1 month after the HF diagnosis date, from the IBM Explorys EMR database. The study period was between January 1st of 2012 and October 31 of 2019 and the HF diagnosis date successfully paired with a qualifying EF measurement was defined as the cohort entry date.

The study protocol was approved by the Brigham and Women's Hospital Institutional Review Board.

Model Validation:

A patient level analytic data file with information on the predictor variables (**Appendix Table 1**) was created for the whole cohort of eligible HF patients from the MarketScan-Explorys linked dataset. All predictors were measured in the 6 months prior to and 1-month post cohort entry. Using the regression coefficients for each individual predictor variables reported in Desai et al.,³ we estimated the probabilities of patient belonging to HF_rEF or HF_pEF and classified patients into one of these two classes using the recommended

cut off. We used EF data from IBM Explorlys to define gold standard classification into HFpEF (LVEF \geq 45%) and HFrEF (LVEF<45%). In case of \geq 1 EF results, values recorded on days closest to the cohort entry dates were used to define the gold standard. The predicted classification was compared against the gold standard to complete this validation exercise.

Statistical analysis

Patient characteristics including demographics, HF-related variables (e.g. diagnosis code recorded for HF, HF-related hospitalizations), HF-related medications and various co-morbid conditions (e.g. hyperlipidemia, hypertension, cardiomyopathy) were described stratified by HFrEF or HFpEF for this validation cohort. We calculated overall accuracy (correct classification rate = number of accurate predictions/number of total predictions), positive predictive value (probability of being a true case, given algorithm prediction) and sensitivity (the probability of being identified as a case of specific HF class by the algorithm for a true case out of the overall population) along with 95% confidence intervals. Further, the performance of this model was also tested in the following pre-specified subgroups: males and females, age <65 and \geq 65 years, index date prior to October 2015 (ICD9 period) and after October 2015 (ICD10 period). It should be noted that we allowed multiple entries in the cohort, therefore some patients may contribute to both the ICD9 and ICD10 period subgroups. We also described patient characteristics in categories of patients accurately and inaccurately classified by our model to characterize misclassified populations.

RESULTS

Study Cohort

We identified 157,203 patients with at least 1 HF diagnosis following 6 months eligibility of continuous medical and pharmacy benefits. Of these patients, we included 7,001 who were at least 18 years old at

cohort entry date and who had at least one EF result available between 180 days before and 30 days after index date. Details of the cohort construction are provided in **Figure 1**.

Figure 1: Cohort consort diagram

Cohort consort Diagram




Table 1 contains data on baseline characteristics by EF class identified via the gold standard criteria using EMR-recorded EF values. We identified 5,301 patients as HFpEF and 1,700 patients as HFrEF. The average age was similar across both the groups (HFpEF =71 years vs HFrEF=69 years) while males comprised 68% of HFrEF compared to 51% of HFpEF. The mean (SD) EF was 59%(7) in the HFpEF group while it was 32%(9) in the HFrEF group.

Table 1: Baseline Characteristics of HF Patients Stratified by Ejection Fraction Class (HFrEF, < 0.45; or HFpEF, ≥0.45)

Variable	Gold standard HFrEF (N=1,700)	Gold standard HFpEF (N=5,301)
	N (%)	N (%)
Mean LVEF (in %), (SD)	32 (9)	59 (7)
Demographics		
Male	1152 (67.76)	2687 (50.69)
Age in years, mean (SD)	69.2 (14.0)	70.6 (13.7)
HF-related variables		
HF-specific ICD-9 and ICD-10 codes		
Systolic HF	657 (38.65)	476 (8.98)
Diastolic HF	83 (4.88)	1360 (25.66)
Left HF	94 (5.53)	239 (4.51)
Unspecified HF	790 (46.47)	2930 (55.27)
HF Hospitalizations, mean (SD)	0.16 (0.37)	0.08 (0.27)
Implantable cardioverter-defibrillator	245 (14.41)	111 (2.09)
HF diagnosis identified in outpatient claims	886 (52.12)	3146 (59.35)
HF-related medication use		
ACE inhibitors	968 (56.94)	2108 (39.77)
Mineralocorticoid receptor antagonists	389 (22.88)	467 (8.81)
Beta blockers	998 (58.71)	2587 (48.80)
Digoxin	101 (5.94)	118 (2.23)
Loop diuretics	952 (56.00)	2489 (46.95)
Nitrates	285 (16.76)	519 (9.79)
Thiazide diuretics	629 (37.00)	1581 (29.82)
Comorbidities		
Atrial fibrillation or flutter	723 (42.53)	1956 (36.90)
Anemia	583 (34.29)	2121 (40.01)
Coronary artery bypass graft	132 (7.76)	292 (5.51)
Cardiomyopathy	789 (46.41)	572 (10.79)
Chronic obstructive pulmonary disease	422 (24.82)	1539 (29.03)
Depression	209 (12.29)	941 (17.75)
Hypertensive nephropathy	241 (14.18)	772 (14.56)
Hyperlipidemia	1063 (62.53)	3356 (63.31)
Hypertension	1365 (80.29)	4375 (82.53)
Hypotension	293 (17.24)	811 (15.30)
Myocardial infarction	436 (25.65)	608 (11.47)

Obesity	324 (19.06)	1277 (24.09)
Other dysrhythmias	1002 (58.94)	2469 (46.58)
Psychosis	539 (31.71)	1964 (37.05)
Rheumatic heart disease	260 (15.29)	994 (18.75)
Sleep apnea	235 (13.82)	950 (17.92)
Stable angina	215 (12.65)	540 (10.19)
Valve disorders	278 (16.35)	1148 (21.66)

Performance of the HF model

The model showed an overall accuracy of 0.81 (95% CI: 0.80-0.82). For HFpEF, the model had sensitivity of 0.96 (95% CI, 0.95-0.97) and PPV of 0.81 (95% CI, 0.81-0.82); while for HFrEF, the sensitivity was 0.32 (95% CI, 0.30-0.34) and PPV was 0.72 (95% CI, 0.69-0.76).

The overall accuracy was similar across the different subgroups; however, some variation was observed in sex subgroups. The overall accuracy was higher among female patients compared to male patients, due to a higher sensitivity and PPV in HFpEF. While, the male subgroup performed better for HFrEF. The model demonstrated very similar performance when using ICD-9 HF diagnoses compared to ICD-10 coded HF diagnoses. This was an important finding as the original model was developed using ICD-9 codes only and these finding support its use for data currently using both ICD-9 and ICD-10 diagnoses codes. Details of the performances of the primary model as well as the subgroup analyses are presented in **Table 2**. Patient characteristics in categories of patients accurately and inaccurately classified by our model are summarized for both HFrEF and HFpEF, in **Appendix Table 2**.

Table 2. Primary Analysis and Subgroup- Specific Performance

Analysis	Overall Accuracy With 95% CIs	Reduced Ejection Fraction		Preserved Ejection Fraction	
		Positive Predicted Value With 95% CIs	Sensitivity With 95% CIs	Positive Predicted Value With 95% CIs	Sensitivity With 95% CIs
Primary analysis	0.81 (0.80 - 0.82)	0.72 (0.69 - 0.76)	0.32 (0.30 - 0.34)	0.81 (0.81 - 0.82)	0.96 (0.95 - 0.97)
Subgroup 1: Age 65–75 y	0.80 (0.78 - 0.82)	0.73 (0.66 - 0.80)	0.32 (0.28 - 0.37)	0.81 (0.79 - 0.83)	0.96 (0.95 - 0.97)
Subgroup 2: Age 75 y and older	0.80 (0.79 - 0.82)	0.73 (0.66 - 0.79)	0.20 (0.17 - 0.23)	0.81 (0.79 - 0.82)	0.98 (0.97 - 0.98)
Subgroup 3: Males	0.77 (0.75 - 0.78)	0.73 (0.69 - 0.77)	0.35 (0.32 - 0.38)	0.77 (0.76 - 0.79)	0.95 (0.94 - 0.95)
Subgroup 4: Females	0.85 (0.84 - 0.86)	0.70 (0.63 - 0.76)	0.27 (0.23 - 0.30)	0.86 (0.85 - 0.88)	0.98 (0.97 - 0.98)
Subgroup 5: Entry HF diagnosis in inpatient claims	0.80 (0.78 - 0.81)	0.76 (0.72 - 0.80)	0.37 (0.34 - 0.40)	0.80 (0.78 - 0.82)	0.96 (0.95 - 0.96)
Subgroup 6: Entry HF diagnosis in outpatient claims	0.81 (0.80 - 0.82)	0.68 (0.63 - 0.73)	0.28 (0.25 - 0.31)	0.83 (0.81 - 0.84)	0.96 (0.96 - 0.97)
Subgroup 7: ICD-9 coded HF	0.80 (0.78 - 0.81)	0.72 (0.66 – 0.77)	0.28 (0.25 – 0.32)	0.80 (0.79 – 0.82)	0.96 (0.96 – 0.97)
Subgroup 8: ICD-10 coded HF	0.79 (0.78 – 0.80)	0.72 (0.68 – 0.75)	0.34 (0.31 – 0.36)	0.80 (0.79 – 0.81)	0.95 (0.95 – 0.96)

DISCUSSION

As EF information is unavailable in administrative claims databases, it is important to develop claims-based models that can be used as a proxy to identify EF classes in patients with HF. In this external validation study, we assessed the accuracy of a claims-based model to predict EF class developed in Medicare data, by applying it to commercial claims data to establish generalizability of this model outside of Medicare claims.

The performance with commercial claims was noted to be equivalent to the performance previously reported for the internal validation sample using Medicare claims.³ In this study, we observed sensitivity of 0.96 and PPV of 0.81 in identifying HFpEF patients. This is very similar to what was reported by Desai et al. in Medicare claims data (sensitivity of 0.97, PPV of 0.84). For HFReEF patients a substantially lower sensitivity (0.32) and a relatively lower PPV (0.72) was seen, which is also consistent with what was previously published (sensitivity of 0.29, PPV of 0.73).

We want to emphasize certain cautions that must be weighed carefully when using this model to identify EF classes in HF. First, the low sensitivity in identifying HFReEF would result in a considerable amount of sample being lost. Further, the group that is identified as HFReEF may systematically differ than the group

that is misclassified by the model. On comparing the accurately classified HF_rEF patients (547) with the misclassified HF_rEF patients (1,153), we observed that EF was lower in accurately classified patients (average of 29% versus 33%, Appendix Table II). Compared to the misclassified HF_rEF patients, the accurately classified HF_rEF patients showed a higher prevalence of HF-related comorbidities, such as cardiomyopathy (85% versus 28%), myocardial infarction (34% versus 21%) and other dysrhythmias (67% versus 55%). Thus, patients identified as HF_rEF by this model represents a sicker group.

Some limitations deserve mention. Although EMR data includes rich clinical information, high amount of missing data is to be expected. Consequently, generalizability may be limited if the patients with recorded EF values are not representative of the full HF population. Further, in the clinical setting, the diagnosis of HF_pEF is typically a diagnosis of exclusion and may require confirmatory information about structural changes of the heart, beyond EF alone. Consequently, even though EF improves the accuracy of the diagnosis, there might be false positive HF_pEF patients.

In conclusion, results from this study provide evidence regarding the generalizability of an approach using claims data to identify EF classes in HF patients outside of Medicare claims. This will aid future studies evaluating health outcomes, healthcare utilization as well as cost of care among HF patients in routine care when EF measurements are not available.

Sources of Funding

This study was supported by a collaborative research grant from Novartis Inc. The study was conducted by the authors independent of the sponsor. The sponsor was given the opportunity to make nonbinding comments on a draft of the manuscript, but the authors retained the right of publication and determined the final wording.

Disclosures

Dr. Desai has received unrestricted research grants from Merck and Bayer for unrelated projects. Dr. Studer and Ms. Lahoz are employees of Novartis Pharma AG. Mr. Kumar is an employee of Novartis Healthcare Pvt. Ltd., India and Dr. Barve is an employee of Novartis Ireland Pvt. Ltd., Ireland. There are no conflicts of interest to disclose for the other co-authors.

REFERENCES

1. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J*. 2016;37(27):2129-2200.
2. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. *Journal of clinical epidemiology*. 2005;58(4):323-337.
3. Desai RJ, Lin KJ, Patorno E, et al. Development and Preliminary Validation of a Medicare Claims-Based Model to Predict Left Ventricular Ejection Fraction Class in Patients With Heart Failure. *Circ Cardiovasc Qual Outcomes*. 2018;11(12):e004700.
4. Kaelber DC, Foster W, Gilder J, Love TE, Jain AK. Patient characteristics associated with venous thromboembolic events: a cohort study using pooled electronic health record data. *J Am Med Inform Assoc*. 2012;19(6):965-972.
5. Maradey-Romero C, Prakash R, Lewis S, Perzynski A, Fass R. The 2011-2014 prevalence of eosinophilic oesophagitis in the elderly amongst 10 million patients in the United States. *Aliment Pharmacol Ther*. 2015;41(10):1016-1022.
6. Sheyn D, James RL, Taylor AK, Sammarco AG, Benckek P, Mahajan ST. Tobacco use as a risk factor for reoperation in patients with stress urinary incontinence: a multi-institutional electronic medical record database analysis. *Int Urogynecol J*. 2015;26(9):1379-1384.
7. Van Fossen VL, Wilhelm SM, Eaton JL, McHenry CR. Association of thyroid, breast and renal cell cancer: a population-based study of the prevalence of second malignancies. *Ann Surg Oncol*. 2013;20(4):1341-1347.

Appendices

Appendix Table 1. Operational definitions for the variables included in the EF class prediction algorithm

Variable	Variable name in SAS algorithm	ICD-9 codes Definition (Codes are ICD-9 diagnosis unless otherwise specified, all medical claims, inpatient and outpatient, should be used to define the conditions unless otherwise specified)	Corresponding ICD-10 Diagnosis / Procedure codes, or prescription codes	When measured
Gender	Male	N/A	N/A	On index date
Age	Age	N/A	N/A	On index date
Systolic heart failure	hf_systolic	ICD-9 code of 428.2x (not co-occurring with 428.3x)	I50.2x (not co-occurring with I50.3x)	On index date
Diastolic heart failure	hf_diastolic	a code of 428.3x (not co-occurring with 428.2x)	I50.3x (not co-occurring with I50.2x)	On index date
Left heart failure	hf_left	a code of 428.1x (not co-occurring with more specific systolic or diastolic HF codes of 428.2x or 428.3x)	I50.1 (not co-occurring with more specific systolic or diastolic HF codes of I50.2x or I50.3x)	On index date
Unspecified heart failure	hf_unspecified	codes of 428.0x, 428.4x, 428.9x as well as instances of recording of both 428.2x and 428.3x	codes of I50.4x, I50.8x, or I50.9 as well as instances of recording of both I50.2x and I50.3x	On index date
Index diagnosis recorded during an outpatient visit	index_dx_out	If index diagnosis occurs in an outpatient claim	N/A	On index date
Number of hospitalizations for CHF	hosp_chf	Count variable where CHF is the primary diagnosis in an inpatient stay	N/A	6 month prior to the index date (including index date)
Implantable cardioverter defibrillator	dx_defibrillator	V45.02 (ICD-9 diagnosis code) 37.94-37.98 (ICD-9 procedure codes)	Z95.810, I (02H60KZ, 02H63KZ, 02H64KZ, 02H70KZ, 02H73KZ, 02H74KZ, 02HK0KZ, 02HK3KZ, 02HK4KZ, 02HL0KZ, 02HL3KZ, 02HL4KZ) + (0JH608Z, 0JH638Z, 0JH808Z,	6 month prior to the index date to (index date+30 days)
Ace inhibitor	rx_ace	Benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril from prescription claims		6 month prior to the index date to (index date+30 days)
Mineralocorticoid receptor antagonist	rx_antagonist	Eplerenone, spironolactone from prescription claims		6 month prior to the index date to (index date+30 days)
Beta blocker	rx_bb blocker	Acebutolol, atenolol, betaxolol, bisoprolol, carteolol, carvedilol, esmolol, labetalol, metoprolol, nadolol, nebivolol, penbutolol, pindolol, propranolol, timolol from prescription claims		6 month prior to the index date to (index date+30 days)
Digoxin	rx_digoxin	Digoxin from prescription claims		6 month prior to the index date to (index date+30 days)
Loop diuretic	rx_loop_diuretic	Bumetanide, furosemide, torsemide, ethacrynic acid from prescription claims		6 month prior to the index date to (index date+30 days)
Nitrate	rx_nitrates	Nitroglycerin, isosorbide dinitrate, isosorbide mononitrate, ranolazine from prescription claims		6 month prior to the index date to (index date+30 days)
Thiazide diuretic	rx_thiazide	Bendroflumethiazide, Benzthiazide, Chlorothiazide, Chlorthalidone, Hydrochlorothiazide, Indapamide, Methyclothiazide, Metolazone, Polythiazide, Quinethazone, Trichlormethiazide from prescription claims		6 month prior to the index date to (index date+30 days)
Atrial fibrillation	dx_afib	427.3x	I48.x	6 month prior to the index date to (index date+30 days)
Anemia	dx_anemia	280.xx	D50.x	6 month prior to the index date to (index date+30 days)
		281.xx	D51.0, D51.1, D51.3, D51.8, D52.0, D52.1, D52.8, D52.9, D53.0, D53.1, D53.8, D53.9	
		282.xx	D58.0, D58.1, D55.0, D55.1, D55.8, D56.x, D57.x, D58.2, D58.8, D58.9	
		283.xx	D59.x	
		284.xx	D61.x	
		285.xx	D50.x, D51.x, D52.x, D53.x, D55.x, D56.x, D57.x, D58.x, D59.x, D60.x, D61.x, D62.x, D63.x, D64.x	
		ICD-9 Procedure		

Coronary artery bypass graft	dx_cabg	36.1x	0210093, 02100A3, 02100I3, 02100K3, 02100Z3, 0210493, 02104A3, 02104I3, 02104K3, 02104Z3, 021008W, 021009W, 02100AW, 02100JW, 02100KW, 021048W, 021049W, 02104AW, 02104JW, 02104KW, 021108W, 021109W, 02110AW, 02110JW, 02110KW, 021148W, 021149W, 02114AW, 02114JW, 02114KW, 021208W, 021209W, 02120AW, 02120JW, 02120KW, 021248W, 021249W, 02124AW, 02124JW, 02124KW, 021308W, 021309W, 02130AW, 02130JW, 02130KW, 021348W, 021349W, 02134AW, 02134JW, 02134KW, 0210088, 0210089, 021008C, 0210098, 0210099, 021009C, 02100A8, 02100A9, 02100AC, 02100I8, 02100I9, 02100IC, 02100K8, 02100K9, 02100KC, 02100Z8, 02100Z9, 02100ZC, 0210488, 0210489, 021048C, 0210498, 0210499, 021049C, 02104A8, 02104A9, 02104AC, 02104I8, 02104I9, 02104IC, 02104K8, 02104K9, 02104KC, 02104Z8, 02104Z9, 02104ZC,	6 month prior to the index date to (index date+30 days) 6 month prior to the index date to (index date+30 days)
			0211088, 0211089, 021108C, 0211098, 0211099, 021109C, 02110A8, 02110A9, 02110AC, 02110I8, 02110I9, 02110IC, 02110K8, 02110K9, 02110KC, 02110Z8, 02110Z9, 02110ZC, 0211488, 0211489, 021148C, 0211498, 0211499, 021149C, 02114A8, 02114A9, 02114AC, 02114I8, 02114I9, 02114IC, 02114K8, 02114K9, 02114KC, 02114Z8, 02114Z9, 02114ZC, 021208C, 021209C, 02120AC, 02120IC, 02120KC, 02120ZC, 021248C, 021249C, 02124AC, 02124IC, 02124KC, 02124ZC, 021308C, 021309C, 02130AC, 02130IC, 02130KC, 02130ZC, 021348C, 021349C, 02134AC, 02134IC, 02134KC, 02134ZC, 021008F, 021009F, 02100AF, 02100IF, 02100KF, 02100ZF, 021048F, 021049F, 02104AF, 02104JF, 02104KF, 02104ZF, 0210083, 0210093, 02100A3, 02100I3, 02100K3, 02100Z3, 0210483, 0210493, 02104A3, 02104I3, 02104K3, 02104Z3	
		36.2x	021K0Z8, 021K0Z9, 021K0ZC, 021K0ZW, 021K4Z8, 021K4Z9, 021K4ZC, 021K4ZW, 021L0Z8, 021L0Z9, 021L0ZC, 021L4Z8, 021L4Z9, 021L4ZC	
		CPT4: 33510 – 33536 33545 33572		
Cardiomyopathy	dx_cardiomyopathy	425.x	I42.x, I43.x	6 month prior to the index date to (index date+30 days)
COPD	dx_copd	491.xx	J41.x, J42.x, J44.x	6 month prior to the index date to (index date+30 days)
		492.xx	J43.x	
		496.xx	J44.9	
		493.2x	J44.0, J44.1, J44.9	
Depression	dx_depression	293.83	F06.30	6 month prior to the index date to (index date+30 days)
		296.2x	F32.x	
		296.3x	F33.x	
		296.9	F34.8, F39.x	
		298.0x	F32.3, F33.3	
		300.4x	F34.1	
		309.1x	F43.21	
		309.2x	F43.23	
		311.xx	F32.9	
Hypertensive nephropathy	dx_htn_nephropathy	403.xx, 404.xx	I12.x, I13.x	6 month prior to the index date to (index date+30 days)
Hyperlipidemia	dx_hyperlipidemia	272.xx	E78.x	6 month prior to the index date to (index date+30 days)
Hypertension	dx_hypertension	401.xx, 402.xx, 405.xx	I10.x, I11.x I15.x, I12.0, I12.9, I13.0, I13.10, I13.11, I13.2	6 month prior to the index date to (index date+30 days)
Hypotension	dx_hypotension	458.xx	I95.x	6 month prior to the index date to (index date+30 days)
Myocardial infarction	dx_mi	410.xx	I21.01, I21.02, I21.09, I21.11, I21.19, I21.21, I21.29, I21.3, I21.4, I22.0, I22.1, I22.2, I22.8, I22.9	6 month prior to the index date to (index date+30 days)
Obesity	dx_obesity	278	E65.x, E66.x, E67.x, E.68.x	6 month prior to the index date to (index date+30 days)
		278.01	E66.01	
		V85.3x	Z68.3x	
		V85.4x	Z68.4x	
		CPT codes		
		'43842', '43843', '43846', '43847', '43848', 'G0443', 'G0447'		
		Prescriptions of orlistat, sibutramine, phentermine, benzphetamine, phendimetrazine, diethylpropion		
		427.0x	I47.0, I47.1	
		427.1x	I47.2	

Other dysrhythmias	dx_oth_dysrhythmia	427.2x	I47.9	6 month prior to the index date to (index date+30 days)
		427.4x	I49.01, I49.02	
		427.6x	I49.40, I49.1, I49.2, I49.3, I49.49	
		427.8x	I49.5, R00.1, I49.8	
		427.9x	I49.9	
		785.0x	R00.0	
Psychosis	dx_psychosis	290.8x, 290.9x, 295.xx, 297.xx, 298.xx, 299.xx, 780.1x	F03.90, F20.X, F22.X, F32.3, F33.3, F28.X, F44.89, F23.X, F29.X, F84.0, F84.3, F84.5, F84.8, F84.9, R44.0, R44.2, R44.3, R55.X, R56.00, R56.01, R56.1, R56.9, R42.X, G47.9, G47.30, G47.00, G47.10, G47.20, G47.8, F51.8, R50.2, R50.9, R50.81, R50.82, R50.83, R68.83, R68.0, R50.84, R53.82, R53.2, G93.3, R53.1, R53.81, R53.83, R61.X, R68.12, R68.11, R41.2, R41.3, R68.81, R45.83, R52.XX, R41.82, R45.84, R68.89, F24, F25.0, F25.1, F25.8, F25.9	6 month prior to the index date to (index date+30 days)
Rheumatic heart disease	dx_rheumatic_heart	393-398.x	I05.XX-I09.XX	6 month prior to the index date to (index date+30 days)
Sleep apnea	dx_sleep_apnea	327.2x	G47.3X	6 month prior to the index date to (index date+30 days)
		780.51	G47.30	
		780.53	G47.30	
		780.57	G47.30	
Stable angina	dx_stable_angina	413.xx	I20.1, I20.8, I20.9, I25.111, I25.118, I25.119, I25.701, I25.708, I25.709, I25.711, I25.718, I25.719, I25.721, I25.728, I25.729, I25.731, I25.738, I25.739, I25.751, I25.758, I25.759, I25.761, I25.768, I25.769, I25.791, I25.798, I25.799	6 month prior to the index date to (index date+30 days)
Valve disorder	dx_valve_disorder	394.x	I05.0, I05.1, I05.2, I05.8, I05.9	6 month prior to the index date to (index date+30 days)
		395.x	I06.0, I06.1, I06.2, I06.8, I06.9	
		396.x	I08.0, I08.8, I08.9	
		397.x	I07.1, I07.2, I07.8, I09.89, I09.1	
		398.9x	I09.9, I09.81, I09.89	
		V42.2	Z95.3	
		V43.3	Z95.2	
		OR		
		ICD-9 procedure code		
		35.1x	02QF0ZZ, 02QG0ZZ, 02QH0ZZ, 02QJ0ZZ, 027F04Z, 027F0DZ, 027F0ZZ, 02NF0ZZ, 02QF0ZZ, 027G04Z, 027G0DZ, 027G0ZZ, 02NG0ZZ, 02QG0ZZ, 02VG0ZZ, 027H04Z, 027H0DZ, 027H0ZZ, 02NH0ZZ, 02QH0ZZ	
		35.2x	02RF07Z, 02RF08Z, 02RF0IZ, 02RF0KZ, 02RF47Z, 02RF48Z, 02RF4KZ, 02RF4JZ, 02RG07Z, 02RG08Z, 02RG0KZ, 02RG37Z, 02RG38Z, 02RG3KZ, 02RG47Z, 02RG48Z, 02RG4KZ, 02RG0JZ, 02RG3JZ, 02RG4JZ, 02RH07Z, 02RH08Z, 02RH0KZ, 02RH47Z, 02RH48Z, 02RH4KZ, 02RH0JZ, 02RH4JZ, 02RJ07Z, 02RJ08Z, 02RJ0KZ, 02RJ37Z, 02RJ38Z, 02RJ3KZ, 02RJ47Z, 02RJ48Z, 02RJ4KZ, 02RJ0JZ, 02RJ3JZ, 02RJ4JZ	
		OR		
		one of the following CPT codes:		
		33660-33665		
		33400-33403		
		33420-33430		
		33460		
		33463-33468		
		33475		
		33496		
0257T				
0258T				
0259T				
0262T				

Appendix Table 2. Baseline Characteristics of HF Patients correctly and incorrectly classified by algorithm compared to Gold standard classification.

Variable	Correctly classified rEF cases	rEF cases incorrectly classified as pEF	Gold standard HF rEF	Correctly classified pEF cases	pEF cases incorrectly classified as rEF	Gold standard HF pEF
	(N=547) N (%)	(N=1,153) N (%)	(N=1,700) N (%)		(N=5,094) N (%)	(N=207) N (%)
Mean LVEF, (SD)	0.29 (0.09)	0.33 (0.08)	0.32 (0.09)	0.59 (0.07)	0.53 (0.07)	0.59 (0.07)
Demographics						
Male	401 (73.31)	751 (65.13)	1152 (67.76)	2542 (49.90)	145 (70.05)	2687 (50.69)
Age, mean (SD)	64.3 (13.7)	71.6 (13.5)	69.2 (14.0)	70.9 (13.5)	62.4 (15.8)	70.6 (13.7)
HF-related variables						
HF-specific ICD-9 and ICD-10 codes						
Systolic HF	398 (72.76)	259 (22.46)	657 (38.65)	343 (6.73)	133 (64.25)	476 (8.98)
Diastolic HF		83 (7.20)	83 (4.88)	1358 (26.66)	2 (0.97)	1360 (25.66)
Left HF	49 (8.96)	45 (3.90)	94 (5.53)	202 (3.97)	37 (17.87)	239 (4.51)
Unspecified HF	77 (14.08)	713 (61.84)	790 (46.47)	2906 (57.05)	24 (11.59)	2930 (55.27)
HF Hospitalizations, mean (SD)	0.22 (0.42)	0.14 (0.34)	0.16 (0.37)	0.08 (0.27)	0.09 (0.28)	0.08 (0.27)
Implantable cardioverter-defibrillator	112 (20.48)	133 (11.54)	245 (14.41)	76 (1.49)	35 (16.91)	111 (2.09)
HF diagnosis identified in outpatient claims	246 (44.97)	640 (55.51)	886 (52.12)	3032 (59.52)	114 (55.07)	3146 (59.35)
HF-related medication use						
ACE inhibitors	363 (66.36)	605 (52.47)	968 (56.94)	1987 (39.01)	121 (58.45)	2108 (39.77)
Mineralocorticoid receptor antagonists	186 (34.00)	203 (17.61)	389 (22.88)	433 (8.50)	34 (16.43)	467 (8.81)
Beta blockers	345 (63.07)	653 (56.63)	998 (58.71)	2446 (48.02)	141 (68.12)	2587 (48.80)
Digoxin	36 (6.58)	65 (5.64)	101 (5.94)	111 (2.18)	7 (3.38)	118 (2.23)
Loop diuretics	323 (59.05)	629 (54.55)	952 (56.00)	2408 (47.27)	81 (39.13)	2489 (46.95)
Nitrates	115 (21.02)	170 (14.74)	285 (16.76)	480 (9.42)	39 (18.84)	519 (9.79)
Thiazide diuretics	238 (43.51)	391 (33.91)	629 (37.00)	1524 (29.92)	57 (27.54)	1581 (29.82)
Comorbidities						
Atrial fibrillation or flutter	204 (37.29)	519 (45.01)	723 (42.53)	1878 (36.87)	78 (37.68)	1956 (36.90)
Anemia	138 (25.23)	445 (38.59)	583 (34.29)	2057 (40.38)	64 (30.92)	2121 (40.01)
Coronary artery bypass graft	36 (6.58)	96 (8.33)	132 (7.76)	283 (5.56)	9 (4.35)	292 (5.51)
Cardiomyopathy	467 (85.37)	322 (27.93)	789 (46.41)	404 (7.93)	168 (81.16)	572 (10.79)
Chronic obstructive pulmonary disease	126 (23.03)	296 (25.67)	422 (24.82)	1497 (29.39)	42 (20.29)	1539 (29.03)
Depression	60 (10.97)	149 (12.92)	209 (12.29)	909 (17.84)	32 (15.46)	941 (17.75)
Hypertensive nephropathy	61 (11.15)	180 (15.61)	241 (14.18)	744 (14.61)	28 (13.53)	772 (14.56)
Hyperlipidemia	312 (57.04)	751 (65.13)	1063 (62.53)	3234 (63.49)	122 (58.94)	3356 (63.31)
Hypertension	413 (75.50)	952 (82.57)	1365 (80.29)	4225 (82.94)	150 (72.46)	4375 (82.53)
Hypotension	97 (17.73)	196 (17.00)	293 (17.24)	781 (15.33)	30 (14.49)	811 (15.30)
Myocardial infarction	189 (34.55)	247 (21.42)	436 (25.65)	531 (10.42)	77 (37.20)	608 (11.47)
Obesity	113 (20.66)	211 (18.30)	324 (19.06)	1228 (24.11)	49 (23.67)	1277 (24.09)
Other dysrhythmias	365 (66.73)	637 (55.25)	1002 (58.94)	2345 (46.03)	124 (59.90)	2469 (46.58)
Psychosis	165 (30.16)	374 (32.44)	539 (31.71)	1896 (37.22)	68 (32.85)	1964 (37.05)
Rheumatic heart disease	67 (12.25)	193 (16.74)	260 (15.29)	960 (18.85)	34 (16.43)	994 (18.75)
Sleep apnea	80 (14.63)	155 (13.44)	235 (13.82)	920 (18.06)	30 (14.49)	950 (17.92)
Stable angina	76 (13.89)	139 (12.06)	215 (12.65)	518 (10.17)	22 (10.63)	540 (10.19)
Valve disorders	69 (12.61)	209 (18.13)	278 (16.35)	1113 (21.85)	35 (16.91)	1148 (21.66)